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TAILOR – tapered discontinuation versus
maintenance therapy of antipsychotic
medication in patients with newly
diagnosed schizophrenia or persistent
delusional disorder in remission of
psychotic symptoms: study protocol for a
randomized clinical trial
Anne Emilie Stürup1,2*, Heidi Dorthe Jensen1, Signe Dolmer3, Merete Birk3, Nikolai Albert1, Mai Nielsen3,
Carsten Hjorthøj1 , Lene Eplov1, Bjørn H. Ebdrup4, Ole Mors3 and Merete Nordentoft1,2
Abstract
Background: The aim of the TAILOR trial is to investigate the effect of closely monitored tapering/discontinuation
versus maintenance therapy with antipsychotic medication in patients with newly diagnosed schizophrenia or
persistent delusional disorder and with minimum 3 months’ remission of psychotic symptoms.
Methods and design: Two hundred and fifty patients will be included from the psychiatric early intervention program,
OPUS, in two regions in Denmark. Inclusion criteria are: ICD-10 diagnoses schizophrenia (F20, except F20.6) or persistent
delusional disorder (F22), minimum 3 months’ remission of psychotic symptoms and in treatment with antipsychotic
medication (except clozapine). The patients will be randomized to maintenance therapy or tapering/discontinuation with
antipsychotic medication in a 1-year intervention. The tapering/discontinuation group will be using a smartphone
application to monitor early warning signs of psychotic relapse. Patients will be assessed at baseline, 1-, 2- and 5-year
follow-up regarding psychotic and negative symptoms, side-effects of antipsychotic medication, social functioning,
cognitive functioning, perceived health status, patient satisfaction, substance and alcohol use, sexual functioning and
quality of life. The primary outcome will be remission of psychotic symptoms and no antipsychotic medication after
1 year. Secondary outcome measures will include: co-occurrence of remission of psychotic symptoms and 0–1-mg
haloperidol equivalents of antipsychotic medication after 1-year intervention; antipsychotic dose; antipsychotic side
effects; negative symptoms; social functioning; cognitive functioning; and patient satisfaction. Exploratory outcomes will
include remission, clinical recovery, substance and alcohol use, sexual functioning, quality of life, self-beliefs of coping
and user experience of support from health workers. Safety measures will include death, admissions to psychiatric
hospital, severe self-harm and psychotic relapses.
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Discussion: The TAILOR trial will contribute knowledge about the effect of tapering/discontinuation of antipsychotic
medication in the early phases of schizophrenia and related disorders and the results may guide future clinical
treatment regimens of antipsychotic treatment.
Trial registration: EU Clinical Trials Register – EudraCT number: 2016-000565-23. Registered on 5 February 2016.
Keywords: Schizophrenia, First-episode psychosis, Early intervention, Antipsychotic medication, Discontinuation,
Tapering, Maintenance therapy, Minimal effective dose, Randomized clinical trial,
Background
Schizophrenia spectrum disorders have major implications
for the individual, family and society [1]. The clinical fea-
tures include psychotic symptoms (hallucinations and delu-
sions), negative symptoms (e.g., alogia, affective flattening,
and avolition) and cognitive impairment of, e.g., memory
and social cognition. All symptom domains may exert a se-
vere impact on level of functioning and quality of life [2, 3].
Antipsychotic medication is often effective in the treat-
ment of psychotic symptoms in schizophrenia spectrum
disorders [4], but it has questionable effects on negative
symptoms [5] and limited effect on cognitive function
[6, 7]. Antipsychotics often reduce the risk of relapse
after remission of psychotic symptoms – at least in the
short term [8]. This is the rationale for recommending
maintenance treatment with antipsychotic medication in
national and international guidelines for the treatment
of schizophrenia [4, 9, 10]. However, current guidelines
do not provide recommendations as to which patients
might be able to discontinue their antipsychotic medica-
tion without relapsing. More knowledge is needed to
give specific and tailored recommendations to the indi-
vidual about treatment with antipsychotic medication.
A large meta-analysis of randomized controlled trials
investigated the effect of antipsychotic medication versus
placebo on relapse prevention [8]. The authors found that
antipsychotic medication reduced the risk of relapse with
60% in patients with a long duration of schizophrenia and
with 47% in patients with first-episode schizophrenia. The
meta-analysis indicated that the difference of relapse in
treatment with antipsychotic medication versus placebo
was lower in studies lasting more than 2 years [8]. The risk
of relapse was not influenced by the duration of time
in stable remission before study entrance, or whether
the patient was in remission or not. Similar results
were later published in a meta-analysis solely on non-
affective first-episode psychosis [11].
There are, however, risks of side effects of all anti-
psychotic medication such as movement disorders,
weight gain, diabetes, cardiovascular disease, sedation
and decreased libido [8, 12, 13]. The degree of side ef-
fects depends on drug, and sometimes, dose [14]. Many
side effects are reversible but some movement disorders,
such as tardive dyskinesia or tardive dystonia, may be
irreversible. Obesity, hyperlipidaemia and diabetes are often
persistent side effects and it is unclear whether they are
irreversible. Especially, second-generation antipsychotics,
which are first-line treatment in schizophrenia, cause
metabolic side effects and a higher risk of cardiovascular
morbidity [14, 15]. This is especially unwanted because
patients with schizophrenia already have an increased
morbidity and mortality [16–18]. The side effects of
antipsychotic medication are generally associated with
reduced quality of life [19].
Studies of first-episode psychosis have shown that
some 50 to 60% of the patients were in remission re-
garding psychotic symptoms at 10-year follow-up [20,
21] and approximately half of the patients had discontin-
ued antipsychotic medication [21, 22]. The studies
showed that a substantial group of patients with first-
episode psychosis in the long term can manage without
antipsychotic medication.
A randomized trial of 128 patients compared mainten-
ance treatment with antipsychotic medication to dose re-
duction [23]. At 7-year follow-up more than 40% of
patients in the dose-reduction group were in stable remis-
sion with no or maximum 1-mg haloperidol equivalent
antipsychotic medication daily compared to only 20% in
the maintenance group [24]. The trial revealed that the
dose-reduction group had a higher risk of relapse in the
beginning of the trial but the relapses did not cause long
hospital admissions and the difference in relapse rate in
the two groups was non-significant at 7-year follow-up
[23–26].
In the TAILOR trial we want to compare maintenance
treatment with closely monitored tapering/discontinuation
of antipsychotic medication in patients with schizophrenia
or persistent delusional disorder. These disorders were
chosen because they both have prolonged durations of
psychotic experiences and the treatment recommendations
for the disorders are similar. Thereby, we will evaluate
whether it is possible to reduce dose and maybe discon-
tinue without relapse of psychotic symptoms. Furthermore,
the TAILOR trial will describe the effects of tapering on
negative symptoms, dose of antipsychotic medication, side
effects of antipsychotic medication, social functioning,
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recovery, cognitive functioning, patient satisfaction, sub-
stance and alcohol use, sexual functioning, quality of life,
self-belief of coping, patients’ experience of support from
health workers, relapses, death and hospital admissions.
We hope that the TAILOR trial contributes to knowledge
about which patients can manage with little or no
antipsychotic medication.
Methods and design
This paper was written in line with the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) 2013 explanation and elaboration: guidance for
protocols of clinical trials [27] and the SPIRIT Checklist
and flow chart were used, see Additional file 1 and Fig. 1.
Aim and objectives
The aim of the TAILOR trial is to investigate the effect of
closely monitored tapering/discontinuation versus main-
tenance therapy with antipsychotic medication in patients
with newly diagnosed schizophrenia or persistent delu-
sional disorder and with minimum 3 months’ remission of
psychotic symptoms.
In the TAILOR trial the following hypotheses will
be tested:
 Primary hypothesis:
1. After 1 year there will be more patients in the
tapering/discontinuation group than in the
maintenance group who will not take antipsychotic
medication and will be in remission of psychotic
symptoms (null hypothesis: no difference in the
tapering/discontinuation group compared to the
maintenance group regarding number of patients
not taking antipsychotic medication with remission
of psychotic symptoms at 1-year follow-up)
 Secondary hypotheses:
1. After 2 years there will be more patients in the
tapering/discontinuation group than in the
Fig. 1 Flow chart of the TAILOR trial
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maintenance group who will not take
antipsychotic medication and will be in remission
of psychotic symptoms (null hypothesis: no
difference in the tapering/discontinuation group
compared to the maintenance group regarding
number of patients not taking antipsychotic
medication with remission of psychotic
symptoms at 2-year follow-up)
2. After the first, second and fifth years there will be
more psychotic relapses in the tapering/
discontinuation group than in the maintenance
group (null hypothesis: no difference in the
tapering/discontinuation group compared to the
maintenance group regarding number of patients
with a psychotic relapse after 1, 2 and 5 years)
3. The prevalence of side effects of antipsychotic
medication at 1-, 2- and 5-year follow-up will be
lower in the tapering/discontinuation group than
in the maintenance group (null hypothesis: no
difference in the tapering/discontinuation group
compared to the maintenance group regarding
side effects after 1, 2 and 5 years)
4. Null hypothesis: level of social functioning will be
the same in the tapering/discontinuation group and
in the maintenance group after 1, 2 and 5 years
5. Null hypothesis: cognitive functioning will be the
same in the tapering/discontinuation group and
in the maintenance group after 1, 2 and 5 years
6. Null hypothesis: clinical recovery will be the same
in the tapering/discontinuation group and in the
maintenance group after 2 and 5 years
7. Null hypothesis: substance and alcohol use will be
the same in the tapering/discontinuation group and
in the maintenance group after 1, 2 and 5 years
Trial design and setting
The TAILOR trial is an investigator-initiated, randomized,
multicentre, assessor-blinded, parallel-group, superiority
designed clinical trial. The trial subjects, their physicians
and contact persons in the OPUS teams will not be
blinded to which treatment the trial subjects are random-
ized to, but the researchers will be blinded [28].
The trial subjects will receive 1-year intervention in their
psychiatric outpatient treatment team, OPUS, in the Capital
Region of Denmark and The Central Denmark Region. A
list of trial sites can be obtained at the sponsor. OPUS is an
outpatient treatment modality for people with first-episode
psychosis, e.g., schizophrenia. It comprises treatment with
antipsychotic medication, cognitive-based case manage-
ment, psychoeducation, family involvement, social skills
training and integration in society [29].
The researchers will be physicians and other health pro-
fessionals, trained in the instruments for the assessments
at inclusion and follow-ups. The health professionals
performing the intervention will work at the OPUS team
and the psychiatrist at the OPUS team will have the treat-
ment responsibility for the patient.
Study population and eligibility criteria
 Inclusion criteria:
1. First treatment in an OPUS team with the
International Classification of Diseases, version 10
(ICD-10) diagnosis schizophrenia (F20, except
F20.6) or persistent delusional disorder (F22). The
diagnosis will be established by the researcher
with the diagnostic semistructured interview
SCAN (Schedule for Clinical Assessment I
Neuropsychiatry [30])
2. Minimum 3 months’ remission of psychotic
symptoms and within the first 11 months of
treatment in the OPUS team. The researchers
will confirm remission with SAPS (Schedule for
Assessment of Positive Symptoms in
Schizophrenia [31]) (all global scores below 3)
3. In treatment with antipsychotic medicine (daily
or depot)
4. Minimum age 18 years, fluent in Danish and
informed consent
 Exclusion criteria:
1. Patients in forensic psychiatry, because Danish
law prohibits any interference with treatment
2. Using treatment with clozapine, which indicates
treatment resistance, why tapering/discontinuation
will carry a high risk of psychotic relapse
3. Pregnancy or breastfeeding
4. Previous admission to a psychiatric hospital due
to a psychotic relapse while treated with
antipsychotic medication or tapering of
antipsychotic medication
 Criteria for discontinuing the intervention:
If the patient, within the year of intervention, meets
exclusion criteria 1, 2 or 3, is no longer treated in an
OPUS team or withdraws informed consent, they
will be excluded from the intervention. The patient
will still be assessed at follow-up or, in case of with-
drawal of consent, be asked to participate in the
follow-up interviews.
Interventions
During the 1-year intervention we compare antipsychotic
maintenance treatment with tapering/discontinuation of
antipsychotic medication. The inclusion process is illus-
trated in Fig. 1. Both intervention groups will be in continu-
ous contact with their OPUS team during the intervention
year and receive usual non-pharmacological treatment in
their OPUS team and one of (or tapering from one of) the
following antipsychotics (active substance): amisulpride,
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aripiprazole, chlorprothixene, haloperidol, haloperidol
decanoate, lurasidone, olanzapine, paliperidone, paliperi-
done palmitate, perphenazine, perphenazine decanoate,
quetiapine, risperidone, sertindole, ziprasidone, zuclo-
penthixol or zuclopenthixol decanoate.
Maintenance treatment:
In Denmark, maintenance treatment is recommended
for at least 1 year after remission [4, 9, 10] and patients in
the maintenance group, therefore, receive treatment as
usual. In the intervention year the patients will continue
taking antipsychotic medication with the possibility to
switch to another antipsychotic medication (the same dose
in haloperidol equivalents) and change dose.
If the effect or side effects of antipsychotic medication re-
quire discontinuation, it is allowed to modify intervention,
and if so, the patient stays in the maintenance group.
Tapering/discontinuation:
Tapering and eventual discontinuation of antipsychotic
medication is managed by the treatment responsible
psychiatrist in the OPUS team. The tapering is tailored
to be: (1) approximately 25% monthly reduction of initial
dose, (2) with at least five half lives between each reduc-
tion, (3) duration of minimum 6 months and (4) with
regular assessments and evaluations. If the initial dose is
above the Minimum Effective Dose (MED) [32] the first
step is 3 months’ tapering to MED, next step dose is
maintained in a 3-month stabilization phase, before the
final step of 3 months’ tapering to discontinuation. If the
initial dose is below MED the first step is skipped. The
tapering/discontinuation is illustrated in Fig. 2.
The patients will be receive a user-developed mobile
phone application to make daily registrations. A next of kin
can add a daily note which will be visible to the patient,
and the health professional at the OPUS team can access
all data from a web portal. The aim is to discover early
warning signs of relapse and thereby enhancing safety.
If the patients experience deterioration (increase in SAPS
from 0/1 to 2 or above, or from 2 to 3 or above, or
individual warning signs evaluated by the clinician as signs
of deterioration) or relapse (see definition in the “Out-
comes” section below) it is recommended to increase the
dose to the most recent effective dose or, if necessary, above
this. Tapering can be resumed after 3 months of remission
of psychotic symptoms; however, this is only if the patient
and physician agree on this. Despite deterioration or relapse
the patient stays in the tapering/discontinuation group. If a
switch of antipsychotic medication is necessary it is recom-
mended that the dose of the new antipsychotic is the same
in haloperidol equivalents as the previous antipsychotic.
To improve adherence patients will have regular visits to
their OPUS team. To control for this the patients’ blood
level of antipsychotics will be checked at baseline and
follow-up. The researchers will do a SAPS phone interview
monthly to evaluate remission of psychotic symptoms.
Outcomes
 Primary outcome:
Remission of psychotic symptoms (SAPS ≤ 2 in all
global scores in minimum 3 months) and no
antipsychotic medication in 3 months, assessed at
1-year follow-up.
 Secondary outcomes:
1. Remission of psychotic symptoms (SAPS ≤ 2 in all
global scores in minimum 3 months) and
antipsychotic medication > 0- and ≤ 1-mg
haloperidol equivalents any given day in the
3 months before 1-year follow-up
2. Antipsychotic dose (haloperidol equivalents) at
1-year follow-up
3. Antipsychotic side effects at 1-year follow-up
4. Negative symptoms measured with the SANS
(Schedule for Assessment of Negative Symptoms
[33]) at 1-year follow-up
5. Social functioning measured with the GSDS
(Groningen Social Disabilities Schedule [34]) at
1-year follow-up
6. Cognitive functioning measured with the BACS
(Brief Assessment of Cognition in Schizophrenia
[35]) at 1-year follow-up
7. Patient satisfaction measured with the CSQ
(Patient Satisfaction Questionnaire [36]) at 1-year
follow-up
 Explorative outcomes:
1. Remission of psychotic symptoms (SAPS ≤ 2 in all
global scores in a minimum of 3 months) and no
antipsychotic medication in 3 months, assessed at
2- and 5-year follow-up
2. Remission of psychotic symptoms (SAPS ≤ 2 in all
global scores in a minimum of 3 months) and
antipsychotic medication > 0- and ≤ 1-mg
haloperidol equivalents on any given day in the
3 months before 2- and 5-year follow-up
3. Antipsychotic dose (haloperidol equivalents) at
2- and 5-year follow-up
4. Antipsychotic side effects at 2- and 5-year follow-up
5. Negative symptoms measured with the SANS at
2- and 5-year follow-up
6. Social functioning measured with the GSDS at
2- and 5-year follow-up
7. Social functioning measured with the PSP
(Personal and Social Performance Scale [37]) and
the GAF (Global Assessment of Function [38]) at
1-, 2- and 5-year follow-up
8. Cognitive functioning measured with the BACS
at 2- and 5-year follow-up
9. Remission measured at 1-, 2- and 5-year follow-up:
remission of psychotic symptoms (SAPS ≤ 2 in all
global scores in a minimum of 3 months), negative
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symptoms (SANS ≤ 2 in all global scores in a
minimum of 3 months) and functional remission
[39] (GSDS ≤ 1 in all roles simultaneously in a
minimum of 3 months)
10.Remission measured at 1-, 2- and 5-year follow-up:
remission of psychotic and negative symptoms in a
minimum of 6 months and functional remission in
a minimum of 6 months
11.Clinical recovery [39] at 2-year follow-up: 2-year
remission of both psychotic and negative
symptoms and functional remission through
2 years and no admissions to psychiatric hospital
the past 2 years [39]
12.Substance and alcohol use measured with time line
follow back [40] at 1-, 2- and 5-year follow-up
13.Sexual functioning measured with the CSFQ
(Changes in Sexual Functioning Questionnaire
[41]) and the SUSY questionnaire from the Danish
Health Interview Survey at 1-, 2- and 5-year
follow-up
14.Quality of life measured with the WHO-5
Well-being Index (WHO-5) [42] and a
question about self-rated health at 1-, 2- and
5-year follow-up
15.Self-belief of coping measured with the GSE
(General Self Efficacy [43]) at 1-, 2- and 5-year
follow-up
16.Patients’ experience of support from health
workers measured with INSPIRE [44] at 1-year
follow-up
17.The EuroQol EQ-5D [45, 46] as a measure of
health-related quality of life at 1, 2 and 5-year
follow-up
 Safety measures:
Incidents of death, suicide, admission to psychiatric
hospital, persistent or significant disability/incapacity,
severe self-harm and psychotic relapse (defined as all
of the four following criteria fulfilled simultaneously:
(1) clinical deterioration in a minimum of 1 week, (2)
consequences (e.g., psychiatric hospital admission or
more visits in the OPUS team), (3) clinician evaluates
the episode as a relapse and (4) SAPS ≥ 4).
One-year data from safety measures and primary,
secondary and exploratory outcomes will all be
analyzed and published. Thereafter, data from 2-year
and, finally, 5-year follow-up will be analyzed and
published.
Sample size
We have conducted sample size calculations on the
primary outcome measure and several of the secondary
outcome measures. In all cases, we have applied a
two-sided level of significance of 5%.
In the 1-year OPUS follow-up study, 73 patients received
OPUS treatment, received antipsychotic medication, and
were in remission of psychotic symptoms (SAPS ≤ 2) [22].
At the 2-year follow-up, 17 (23.3%) of these patients were
still in remission but no longer took antipsychotic medica-
tion (See Table 1). This was achieved without a systematic
effort towards dose reduction. This number of patients in
Fig. 2 The tapering/discontinuation intervention
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this group is comparable to the expected number for our
control group (see Table 1). Based on this number, the
sample size calculation was performed with alpha = 0.05
and 80% power to detect the minimum relevant difference
if the tapering/discontinuation group at 1-year follow-up
has an event rate of 39.7% on remission without anti-
psychotic medication (see Table 1). This yields a required
sample size of 125 patients in each group, i.e., a total of 250
patients in the TAILOR trial.
In a Dutch dose-reduction trial 21.5% of patients in the
dose-reduction group were off medication (max 1-mg
haloperidol equivalents daily) and in remission at 18-month
follow-up, which was only the case for 4.8% in the
maintenance-treatment group [23] (see Table 1). The
7-year follow-up of the same study showed that 17.6%
of participants in the maintenance group achieved recovery,
compared to 40.4% in the dose-reduction group [24]. For
secondary outcome 1 (remission of psychotic symptoms
and max 1 mg haloperidol daily) and exploratory outcome
11 (recovery), the power calculations in Table 1 are based
on the references’ numbers for maintenance treatment, and
the numbers for the tapering/discontinuation group is the
minimally detectable difference with 80% power and
2 × 125 participants. For the continuous outcome
measures we have estimated the power we have to de-
tect the lowest clinically relevant difference indentified
from previous studies at alpha = 0.05 to be 2 × 125
participants and the expected standard deviation from
these studies (Table 2). Regarding our exploratory
outcome on the GAF scale, we expect a standard
deviation of 15 [47] and lowest clinically relevant differ-
ence of 5, for which we will have a power of 75%.
Recruitment and allocation
Participants will be recruited from OPUS teams and re-
ferred by team physicians (Fig. 1). To achieve a sufficient
number of participants the physicians are informed
about the TAILOR trial, distribute information material
to the patients, and the TAILOR trial has a website with
information. If necessary, the time for recruitment will
be prolonged.
The randomization will take place after baseline inter-
view and is centralized and computer-based with a hidden
allocation sequence. The researchers and clinicians are
blinded to the randomization block sizes. Factors for
stratification are region (Capital Region of Denmark/The
Central Denmark Region) and harmful use or dependence
on psychoactive substances (ICD-10 diagnosis of F1x.1
and F1x.2 except F17.x) (yes/no). The program OPEN
Randomize [48] will generate the randomization and use
the correct randomization table from the four strata. Each
patient enrolled in the TAILOR trial will be assigned a ser-
ial number before randomization and an email of assigned
randomization will be sent to the health professionals per-
forming the intervention in the OPUS team. A list of pa-
tients’ assigned randomization will be kept at the research
team’s secretary. The randomization code will be stored at
OPEN, Odense Patient data Explorative Network, at The
University of Southern Denmark.
Blinding
The researchers are blinded when performing assess-
ments at baseline, during the intervention year and at
follow-ups. If they are unblinded another researcher will
do the assessment. The clinicians and patients are not
blinded. The researchers will perform the analyses and
draft of conclusions blinded. Unblinding is permissible
and possibly necessary if serious adverse events (SAEs)),
serious adverse reactions (SARs) or suspected unex-
pected serious adverse reactions (SUSARs) occur.
Data collection methods and management
Plans for collection of data at baseline and follow-up as-
sessments are outlined in Fig. 3. Data on patients who do
not complete the intervention will also be collected. Data
Collection Forms are electronic in REDCap (Research
Electronic Data Capture) [49] or on paper and stored by
the principal investigator. To ensure data quality assessors
are trained in the interview instruments, certified in the
SCAN, the BACS and the GSDS and will do regular co-
ratings of live interviews. Interrater reliability of the SAPS
and the SANS will be calculated before the beginning of
the TAILOR trial.
The assessors will enter data from the patient interview
directly into the electronic Case Report Form (CRF) using
the data entry system REDCap [49]. REDCap is an elec-
tronic data capture tool hosted at CIMT in the Capital
Region of Denmark. When necessary, the collection will be
done on paper and later entered electronically and with
double data entry. REDCap has a complete audit trail on all
data transactions, detailed user rights and access control
management and thereby complies with Danish legislation
Table 1 Detectable differences for dichotomous outcome
measures
Outcome Tapering/
discontinuation
Maintenance
treatment
Reference
Remission and no
antipsychotics (primary
outcome)
39.7% 23.3% Godtfredsen
[21]
Stable remission of
psychotic symptoms
and max 1-mg
haloperidol equivalents
(most important
secondary outcome
measure)
15.4% 4.8% Wunderink
[22]
Percentage in recovery
after 7 years (exploratory
outcome measure)
33.4% 17.6% Wunderink
[23]
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(the Act on Processing Personal Data). Data for each pa-
tient is connected to a unique serial number. Only
assigned researchers and Good Clinical Practice (GCP)
monitors can access REDCap with all the data. Data on
paper is stored locally and secured. Research data will be
exported from REDCap without personal identifiers, as-
sembled in a SPSS file and put in logged folders on a net-
work drive under the control of the Capital Region of
Denmark, CIMT. Sources of data are, for example, patient
interview, blood sample values, waist circumference, blood
pressure, patient files and registries. Sponsor and the
principal investigators ensures that data is stored for at
least 10 years after end of trial.
The patients participating in the TAILOR trial will
receive a gift voucher at each follow-up, irrespective of
randomization group, remission and medicine. This is to
ensure participant retention and complete follow-up.
The patients receive an invitation for follow-up in a
letter, by email, or by a phone call.
Statistical methods
The primary outcome measure will be analyzed with binary
logistic regression to estimate the odds ratio for a successful
tapering/discontinuation between the two groups. Other di-
chotomous outcome measures will likewise be analyzed
with logistic regression. Continuous outcome measures will
be controlled for whether they are normal distributed, and
if so the comparison between groups will be done with gen-
eral linear models. Non-parametric tests will performed on
data which is not normally distributed. In all cases the
following variables will be included in the analytical models:
randomization (tapering/discontinuation versus mainten-
ance), region (Central Denmark Region versus Capital
Region of Denmark) and harmful use or dependence of
psychoactive substances (yes versus no). The analyses will
also include variables which, despite randomization, are
skewed between the two groups. Interim analyses will not
be done. All analyses will be by intention-to-treat and all in-
cluded patients will be a part of the analyses regardless of
whether they start the intervention or complete it. Missing
data will be dealt with by multiple imputations. These im-
putations will be done with the baseline value of the vari-
able and baseline values of variables which are predictive
for attrition. Region (Central Denmark Region versus
Capital Region of Denmark) and harmful use or depend-
ence of psychoactive substances (yes versus no) will be part
of the imputation models. Imputations will be done separ-
ately for each group. The continuous variables will be im-
puted with predictive mean matching with three nearest
neighbors. For binary variables we will impute with binary
logistic regression. For multinomial variables we will im-
pute with multinomial logistic regression. For ordinal vari-
ables we will impute with ordinal logistic regression. In
every case we will do 100 imputations. Analyses will be
done after the last 1-year follow-up interview and will ini-
tially be done blinded for randomization and the groups
will instead be named “A” and “B.”
The current publication of the original statistical pro-
cedures will ensure that the TAILOR trial is conducted
and analyzed as planned. Possible deviations and reasons
for those will be described in publications. All data pub-
lished will be verified for authenticity by controlling in-
ternal inconsistency. All results, positive, negative as
well as inconclusive, will be published as quick as pos-
sible and still in concordance with Danish law on pro-
tection of confidentially and personal information.
Results will be presented at national and international
scientific conferences.
Data monitoring and auditing
The TAILOR trial is monitored by the GCP Unit at Aalborg
and Aarhus University Hospitals and the GCP unit at
Copenhagen University Hospital to ensure safety and data
quality according to Good Clinical Practice – The Inter-
national Council for Harmonization of Technical Require-
ments for Pharmaceuticals for Human Use (GCP-ICH) and
Danish laws and regulations. The sponsor is responsible for
the completion and quality of the TAILOR trial. The GCP
Table 2 Power calculations for continuous outcome measures
Outcome Lowest clinically
relevant difference
Expected standard
deviation
Calculated
power
Reference
Antipsychotic haloperidol equivalents 1.5 3 98% Own unpublished data
Negative symptoms (negative dimension,
based on mean of four global SANS scores)
0.4 1.2 75% Petersen [45]
Cognition, overall score (BACS total) 15 42 80% Melau [46]
Client satisfaction (CSQ) 2 5 88% Petersen [45]
Social function (GSDS) 1.6 4.5 80% Standard deviation based on [22].
Lowest clinically relevant difference
is not known, but is set to Cohen’s
d = 0.356, i.e.,low-to-moderate effect size
CSQ Patient Satisfaction Questionnaire, BACS Brief Assessment of Cognition in Schizophrenia, GSDS, Groningen Social Disabilities Schedule, SANS Schedule for
Assessment of Negative Symptoms
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units are independent of sponsor and investigators. The fol-
lowing describes the GCP units’ monitoring and auditing
plan. The following data for included patients will be
checked if they are correct: informed consent, inclusion, ex-
clusion, randomization, allocation, exclusion from interven-
tion, baseline at 1-year follow-up and the primary outcome
measure. At 2- and 5-year follow-up a sampling of 10% of
all included patients will be done regarding check of
follow-up is done at the correct time. Every year it is
checked that all relevant documents are in the trial master
file. It will be monitored that assessments, analyses and
procedures are done as described in the study protocol. It is
also checked that all patients after a half year of interven-
tion in the discontinuation/tapering group have reached
MED or below and in the maintenance group still receive
antipsychotic medication. All reports of SAEs or SARs are
checked for completeness regarding time and information
and that they have been evaluated by authorized personnel
whether there is a link between trial medication and the
SAEs or SARs. The principal investigators allow the GCP
units, the Danish Medicines Agency and the Danish Health
Authority access to data for monitoring, auditing and in-
spection. The plan for monitoring will be evaluated con-
tinuously if necessary.
Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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Safety
In the OPUS team the clinicians will, during the year of
intervention, register adverse events (AEs)/adverse reaction
(ARs) and report all SAEs/SARs to the regional investigator.
It is the physician responsible for the antipsychotic treat-
ment who will evaluate whether the AE/AR is considered
to be a SAE/SAR. Other events or side effects will be
collected from patient files and registers. SAEs, SARs and
SUSARs are defined by the GCP-ICH guideline. Admission
to a psychiatric hospital because of psychosis-related symp-
toms is to be expected in the TAILOR trial and will,
although they are SAEs/SARs, only be reported yearly to
the Danish Medical Agency and the Research Ethics
Committee. The following will not be reported as SAEs/
SARs: (1) clinical deterioration that does not result in ad-
mission to a psychiatric hospital, (2) ordinary side effects
such as gastrointestinal side effects or headaches and (3)
well-known discontinuation withdrawal effects such as
weight loss, sleep disorders, fatigue, increased sweating, in-
attention, raised pulse or anxiety. In the TAILOR trial the
reference to evaluate all events and reactions reported is
the Summary of Product Characteristics of the antipsy-
chotics. The evaluation of causality will be done by the
physician responsible for treatment.
Four times a year all investigators are informed of all
AEs/ARs in the trial. The sponsor will be informed of
SEs/SARs within 24 h without regards to whether the
event is related to the antipsychotic medication. The
sponsor evaluates whether the SAE/SAR is a SUSAR.
Every year during the trial Research Ethics Committee
will receive a report of all SAEs/SARs and SUSARs and
about the safety of the TAILOR trial. In case of a SUSAR
the Research Ethics Committee will be informed imme-
diately. The sponsor will inform the Danish Medicines
Agency in case of a SUSAR and the reporting will be
within 7 days in case of death or life-threatening condi-
tion or else within 15 days. All relevant information on
the sponsor’s and investigators’ follow-up on the SUSAR
will be reported to the Danish Medicines Agency no
later than 8 days after the initial reporting. SAEs/SARs
and SUSARs will be followed until they are dealt with. A
committee consisting of the sponsor, principal investiga-
tors and representatives from outside the TAILOR trial
will evaluate whether an SAE/SAR should result in end
of trial. After the end of the trial the sponsor will make a
report to the Danish Medicines Agency of all SAEs/
SARs during the trial and about the patients’ safety. The
investigator and sponsor will report all side effects and
events to the Research Ethics Committee after the end
of the trial.
The patients in the TAILOR trial are ensured by Danish
law and the patient care regulation.
Every patient in the TAILOR trial will have access to their
own results of the trial if they wish to. The clinicians will
not have access to data collected from assessments done by
the researchers.
Discussion
The TAILOR trial raises ethical, practical and organizational
challenges.
When designing the TAILOR trial ethical questions
were raised regarding blinding and the design of the in-
terventions. In the TAILOR trial only the researchers are
blinded, neither clinicians nor patients, because they
should be attentive of the high risk of relapse in the dis-
continuation group. The design of both interventions
gives the clinicians the possibility to adjust the dose of
the antipsychotic medication to ensure sufficient treat-
ment. Therefore, the TAILOR trial only includes assessor
blinding and the interventions might end up being more
similar than intended and there is a risk that the patient
and physician will misinterpret warnings signs or side ef-
fects. In general, it is of ethical consideration that the
trial participants in the tapering/discontinuation group
will be subjected to a higher risk of relapse. On the other
hand, it seems unethical if research were not to discover
the group of patients who can discontinue antipsychotic
medication without relapsing. The trial participants in
the maintenance group might be subjected to an inter-
vention which no longer exists in the clinical setting and
thereby be maintained on antipsychotic treatment longer
than they would outside the experiment.
Practical challenges will be sufficient recruitment or pa-
tient dropout. Organizational structures will influence the
completion of interventions as they are done in a clinical
setting, which might influence recruitment and intervention.
The TAILOR trial is a complex medical intervention,
which makes it difficult to know which components are
more effective than others. We have ensured good
fidelity by monitoring by the GCP Units in Aarhus and
Copenhagen, but beyond this we have not planned a
qualitative process evaluation.
Overall, we believe that the TAILOR trial will contribute
to knowledge about the effect of tapering/discontinuation
of antipsychotic medication in early phases of schizophrenia
spectrum disorders and that the results may guide future
clinical treatment regimens of antipsychotic medication.
Trial status
Inclusion of patients will start in May 2017.
Additional files
Additional file 1: SPIRIT Checklist. (DOCX 60 kb)
Additional file 2: Model Consent Form for Region Midt. (DOCX 33 kb)
Additional file 3: Model Consent Form for Region Hovedstaden.
(DOCX 37 kb)
Stürup et al. Trials  (2017) 18:445 Page 10 of 12
Abbreviations
AE: Adverse event; AR: Adverse reaction; BACS: Brief Assessment of
Cognition in Schizophrenia; CRF: Case Report Form; CSFQ: Changes in
Sexual Functioning Questionnaire; CSQ: Patient Satisfaction
Questionnaire; GAF: Global Assessment of Function; GCP: Good Clinical
Practice; GCP-ICH: Good Clinical Practice - The International Council for
Harmonization of Technical Requirements for Pharmaceuticals for
Human Use; GSDS: Groningen Social Disabilities Schedule; GSE: General
Self Efficacy; MED: Minimum effective dose; PSP: Personal and Social
Performance Scale; SAE: Serious adverse event; SANS: Schedule for
Assessment of Negative Symptoms; SAPS: Schedule for Assessment of
Positive Symptoms; SAR: Serious adverse reaction; SCAN: Schedule for
Clinical Assessment in Neuropsychiatry; SD: Standard deviation;
SUSAR: Suspected unexpected serious adverse reaction; UKU: Udvalg
for Kliniske Undersøgelser
Acknowledgements
We thank all of our collaborators.
Funding
The TAILOR trial is funded by TrygFonden in Denmark, The Capital Region of
Denmark and The Medication Fund of the Regions of Denmark. A part of the
materials and manpower in the intervention is funded by the Capital Region
of Denmark and The Central Denmark Region. The funders have no role in
the study design, collection, management, analysis and interpretation of
data, writing the report or the decision to submit the report for publication.
Availability of data and materials
Not applicable as data is not yet available.
Authors’ contributions
MN is the trial sponsor, has directed the planning of the study design and
will take part in the analyzing and interpretation of data and the decision to
submit the report for publication. She has the authority over the project. MN
and OM are primary initiators of the project and both are principal
investigators. The Steering Committee consists of MN, OM, LE, BE and CH.
Their role is decision-making on project design, alterations, cooperation,
budget and data handling. The development of the protocol is done in
collaboration by MN, OM, LE, BE, CH, AES, SD, HJ and MB. Writing of the
protocol and design article is primarily done by the AES, the “Background” section
is primarily written by MN and the statistical plan by CH. The rest of the authors
have done critical revision. All authors approved the final version. Authorship for
this and future publications will follow the rules of ICMJE 2015 [50] and the Danish
Code of Conduct for Research [51]. The exact order of merit will depend on each
author’s contribution [52].
Ethics approval and consent to participate
The trial has been approved by the Regional Research Ethics Committee in the
Capital Region of Denmark on 8 September 2016 with file number H-16028814
and the amendment of 3 March 2017 with file number 57222. Informed consent
will be collected by interview with the researcher (Additional files 2 and 3,
depending on center). The patient will have time to consider and ask questions.
The interview will be planned beforehand and take place in a room without other
people except a possible assessor.
Any substantial changes in the protocol will be reported to the Regional
Ethical Committee in the Capital Region of Denmark and the Danish
Medicines Agency. A list of changes and amendments that is required to be
reported can be found on the committee’s and the agency’s websites.
Consent for publication
Not applicable.
Competing interests
Dr. Ebdrup has received lecture fees from, and/or is part of, the Advisory
Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka
Pharma Scandinavia and Takeda Pharmaceutical Company. The remaining
authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Copenhagen University Hospital, Mental Health Center Copenhagen,
Kildegårsvej 28, opg. 15 4. sal, 2900 Hellerup, Denmark. 2University of
Copenhagen, Institute for Clinical Medicine, Faculty of Health and Medical
Science, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. 3Psychosis Research
Unit, Aarhus University Hospital, Skovagervej 2, 8240 Risskov, Denmark.
4Centre for Clinical Intervention and Neuropsychiatric Schizophrenia
Research (CINS) and Centre for Neuropsychiatric Schizophrenia Research
(CNSR), Mental Health Centre Glostrup, Copenhagen University Hospital,
Nordre Ringvej 69, 2600 Glostrup, Denmark.
Received: 3 July 2017 Accepted: 8 September 2017
References
1. Insel TR. Rethinking schizophrenia. Nature. Nature Publishing Group; 2010;
468:187–93.
2. Austin SF, Mors O, Secher RG, Hjorthøj C, Albert N, Bertelsen M, et al.
Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year
follow-up. Schizophr Res. 2013;150:163–8.
3. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ.
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Neuropsychology. 2009;23:315–36.
4. National Institute for Health and Care Excellence (NICE). Psychosis and
schizophrenia in adults: prevention and management—Clinical Guideline. 2014.
5. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S,
et al. Treatments of negative symptoms in schizophrenia: meta-analysis of
168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892–9.
6. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical
antipsychotic drugs on neurocognitive impairment in schizophrenia: a
review and meta-analysis. Schizophr Bull. 1999;25:201–22.
7. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects
of conventional neuroleptic treatment on cognition in schizophrenia:
opening a closed book. Biol Psychiatry. 2004;55(10):1013–22.
8. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al.
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia:
a systematic review and meta-analysis. Lancet. 2012;379:2063–71.
9. American Psychiatric Association (APA). Practice guideline for the treatment of
patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.
10. Fink-Jensen A, Rasmussen I, Viuff AG, Larsen JT, Schmidt M, Peacock L, et al.
Behandlingsvejledning inklusiv lægemiddelrekommandation for medicinsk
behandling af psykotiske tilstande hos voksne [Internet]. RADS—Raadet
Anvendelse af Dyr Sygehusmedicin. 2014. p. 1–6. Available from: http://
docplayer.dk/23054685-Behandlingsvejledning-inklusiv-laegemiddelrekom
mandation-for-medicinsk-behandling-af-psykotiske-tilstande-hos-voksne.html.
Accessed 25 Sept 2017.
11. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with
medication discontinuation in first-episode psychosis: a systematic review.
Schizophr Res. 2014;152(2-3):408–14.
12. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al.
Antipsychotic effects on estimated 10-year coronary heart disease risk in the
CATIE schizophrenia study. Schizophr Res. 2008;105:175–87.
13. Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS.
Metabolic risk factors in first-episode schizophrenia: baseline prevalence
and course analysed from the European First-Episode Schizophrenia Trial.
Int J Neuropsychopharmacol. 2013;16:987–95.
14. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation
versus first-generation antipsychotic drugs for schizophrenia: a meta-
analysis. Lancet. 2009;373:31–41.
15. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and
cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev
Endocrinol. 2011;8:114–26.
16. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost
and life expectancy in schizophrenia: a systematic review and meta-analysis.
Lancet Psychiatry. 2017;4:295–301.
17. Nordentoft M, Wahlbeck K, Hällgren J, Westman J, Ösby U, Alinaghizadeh H,
et al. Excess mortality, causes of death and life expectancy in 270,770
patients with recent onset of mental disorders in Denmark, Finland and
Sweden. PLoS One. 2013;8(1):e55176.
18. Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, et al.
Endogenous and antipsychotic-related risks for diabetes mellitus in young
Stürup et al. Trials  (2017) 18:445 Page 11 of 12
people with schizophrenia: a Danish population-based cohort study. Am J
Psychiatry. American Psychiatric Association Arlington, VA; 2017; appi.ajp.
2016.1. Available from: http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.
2016.16040442. Accessed 25 Sept 2017.
19. Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M. Quality of life
in schizophrenic patients. Dialogues Clin Neurosci. 2007;9(2):215–26.
20. Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M,
et al. Long-term trajectories of positive and negative symptoms in first
episode psychosis: a 10 year follow-up study in the OPUS cohort. Schizophr
Res. 2015;168:84–91.
21. Morgan C, Lappin J, Heslin M, Donoghue K, Lomas B, Reininghaus U, et al.
Reappraising the long-term course and outcome of psychotic disorders: the
AESOP-10 study. Psychol Med. 2014;44:2713–26.
22. Gotfredsen D, Wils RS, Hjorthøj C, Austin SF, Albert N, Secher RG, et al.
Stability and development of psychotic symptoms and the use of
antipsychotic medication—long-term follow-up. Psychol Med. 2017;47(12):
2118–29.
23. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D.
Guided discontinuation versus maintenance treatment in remitted first-
episode psychosis: relapse rates and functional outcome. J Clin Psychiatry.
2007;68:654–61.
24. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in
remitted first-episode psychosis at 7 years of follow-up of an early dose
reduction/discontinuation or maintenance treatment strategy. JAMA
Psychiat. 2013;70:913.
25. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in
schizophrenic patients. Arch Gen Psychiatry. 1995;52:173–88.
26. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al.
Clinical outcome following neuroleptic discontinuation in patients with
remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158:1835–42.
27. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
trials. BMJ. 2013;346:e7586.
28. Nordentoft M, Melau M, Iversen T, Petersen L, Jeppesen P, Thorup A, et al.
From research to practice: how OPUS treatment was accepted and
implemented throughout Denmark. Early Interv Psychiatry. 2015;9:156–62.
29. Albert N, Melau M, Jensen H, Emborg C, Jepsen JRM, Fagerlund B, et al. Five
years of specialised early intervention versus two years of specialised early
intervention followed by three years of standard treatment for patients with
a first episode psychosis: randomised, superiority, parallel group trial in
Denmark (OPUS II). BMJ. 2017;356:i6681.
30. Wing JK, Sartorius N, Üstun TB. WHO diagnosis and clinical measurement in
psychiatry. A reference manual for SCAN. Cambridge: Cambridge University
Press; 1998.
31. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS).
Iowa City: The University of Iowa; 1984.
32. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose
equivalents for second-generation antipsychotics: the minimum effective
dose method. Schizophr Bull. 2014;40:314–26.
33. Andreasen NC, Flaum M, Swayze 2nd V, Tyrrell G, Arndt S. Positive and
negative symptoms in schizophrenia: a critical reappraisal. Arch Gen
Psychiatry. 1990;47:615–21.
34. Wiersma D, DeJong A, Ormel J. The Groningen Social Disabilities Schedule.
Int J Rehabil Res. 1988;11:213–24.
35. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The
Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and
comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:
283–97.
36. Attkisson CC, Zwick R. The Client Satisfaction Questionnaire. Eval Program
Plann. 1982;5:233–7.
37. Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect
change of the Personal and Social Performance Scale in patients with stable
schizophrenia. Psychiatry Res. 2008;161:213–24.
38. Pedersen G, Hagtvet KA, Karterud S. Generalizability studies of the Global
Assessment of Functioning-Split version. Compr Psychiatry. 2007;48:88–94.
39. Wunderink L, Sytema S, Nienhuis FJ, Wiersma D. Clinical recovery in first-
episode psychosis. Schizophr Bull. 2009;35:362–9.
40. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E. The reliability of a
timeline method for assessing normal drinker college students’ recent
drinking history: utility for alcohol research. Addict Behav. 1986;11:149–61.
41. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the
Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex
Marital Ther. 2006;32:43–52.
42. Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-being
Index: a systematic review of the literature. Psychother Psychosom. 2015;84:
167–76.
43. Schwarzer R, Jerusalem M. The General Self-Efficacy Scale (GSE) [Internet].
Available from: http://www.midss.org/content/general-self-efficacy-scale-
gse. Accessed 25 Sept 2017.
44. Williams J, Leamy M, Bird V, Le Boutillier C, Norton S, Pesola F, et al.
Development and evaluation of the INSPIRE measure of staff support for
personal recovery. Soc Psychiatry Psychiatr Epidemiol. 2015;50:777–86.
45. Hastrup LH, Nordentoft M, Hjorthøj C, Gyrd-Hansen D. Does the EQ-5D
measure quality of life in schizophrenia? J Ment Health Policy Econ.
Psychiatric Research Unit, Region Zealand, Roskilde, Denmark.
lhhs@regionsjaelland.dk; 2011;14:187–96.
46. Brooks R. EuroQol: the current state of play. Health Policy (New. York).
[Internet]. 1996;37:53–72. Available from: http://www.sciencedirect.com/
science/article/pii/0168851096008226.
47. Petersen L, Jeppesen P, Thorup A, Abel M-B, Øhlenschlaeger J, Christensen TØ, et
al. A randomised multicentre trial of integrated versus standard treatment for
patients with a first episode of psychotic illness. BMJ Br Med J. 2005;331:602.
48. Odense Patient Data Explorative Network. OPEN Randomize [Internet].
Available from: http://www.sdu.dk/en/om_sdu/institutter_centre/klinisk_
institut/forskning/forskningsenheder/open/opens_faciliteter/open
+randomise. Accessed 25 Sept 2017.
49. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
data capture (REDCap)—A metadata-driven methodology and workflow process
for providing translational research informatics support. J Biomed Inform. 2009;42:
377–81.
50. International Committee of Medical Journal Editors. Recommendations for the
conduct, reporting, editing, and publication of scholarly work in medical journals
[Internet]. Available from: http://www.icmje.org. Accessed 25 Sept 2017.
51. Ministry of Higher Education and Science. The Danish Code of Conduct for
Research Integrity [Internet]. 2014. Available from: http://ufm.dk/
publikationer/2014/filer-2014/the-danish-code-of-conduct-for-research-
integrity.pdf. Accessed 25 Sept 2017.
52. Beveridge C, Morris S. Order of merit. Nature. 2007;448:508.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Stürup et al. Trials  (2017) 18:445 Page 12 of 12
